Biotech

All Articles

Amgen files first stage 3 win for $400M dermatitis drug

.Amgen has shared (PDF) the initial period 3 data on its $400 million eczema drug, connecting the an...

Biogen, UCB report period 3 lupus gain after failing earlier test

.Biogen and UCB's rely on improving in to phase 3 astride an unsuccessful research looks to have rep...

Aptadir wishes brand new RNA inhibitors can easily turn around tricky cancers cells

.Italian biotech Aptadir Therapeutics has actually released along with the promise that its pipe of ...

Wave surfs DMD results to regulatory authorities' doors, sending out stock up

.Wave Lifestyle Sciences has met its own target in a Duchenne muscle dystrophy (DMD) study, position...

Sanofi picks brand-new CSO coming from in-stealth biotech

.After a few years in biotech, Mike Quigley, Ph.D., is coming back to the pharma fold, using up the ...

Achilles droplets tissue therapy system, braces for layoffs after missing out on 'commercial feasibility' objectives

.Achilles Therapeutics has shreded its method. The British biotech is actually quiting working on it...

Aligos proclaims period 2 MASH win, lowering liver excess fat as much as 46%

.Aligos Therapeutics is heralding a midstage gain in metabolic-dysfunction associated steatohepatiti...

Basilea credit ratings $268M BARDA backing for antifungals, antibiotics

.Basilea Pharmaceutica's job building brand new antifungals has gotten a significant boost from the ...

Capricor offers Europe rights to late-stage DMD treatment for $35M

.Possessing actually gathered up the U.S. civil liberties to Capricor Therapeutics' late-stage Duche...

FDA fragments adcomm for Applied's unusual condition medicine

.After pushing back the decision date for Applied Therapies' metabolic condition medication govorest...